-

Lost Money in NeoGenomics, Inc.?

Gibbs Law Group Investigates Potential Securities Law Violations

OAKLAND, Calif.--(BUSINESS WIRE)--Shares of NeoGenomics Inc. dropped more than 20% on March 28th, 2022, after the company announced disappointing guidance in its quarterly report, as well as the departure of its CEO Mark Mallon. Gibbs Law Group is investigating a potential NeoGenomics Securities Class Action Lawsuit on behalf of shareholders who lost money in NeoGenomics Inc. (NASDAQ: NEO).

To speak with an attorney regarding this class action lawsuit investigation, click here or call (888) 410-2925.

On Monday, March 28th, 2022, shares of the health-testing company NeoGenomics dropped sharply after announcing in its quarterly report that Mark Mallon will be stepping down after only a year as company CEO, and that the company will miss guidance and rescind its forecast for the entire year. According to Marketwatch, NeoGenomics’ stock has been slipping since a November report announced disappointing guidance. In the past six months, the company has lost more than 60% of its value, dropping from a market capitalization of $6 billion at times, to around $2.2 billion at market close on Monday March 28th.

According to Investor’s Business Daily, Needham analyst Mike Matson stated the possibility that Mallon invested too much in NeoGenomics minimum residual disease test, which searches for cancer in a patient’s blood following treatment. These investments would have affected NeoGenomics’ earnings before interest, taxes, depreciation and amortization, or EBITDA.

Following this news, NeoGenomics’ stock price plummeted more than 20% on March 28th, 2022, causing significant harm to investors.

What Should NeoGenomics Investors Do?

If you invested in NeoGenomics, visit our website or contact our securities team directly at (888) 410-2925 to discuss how you may be able to recover your losses. Our investigation concerns whether NeoGenomics has violated federal securities laws by providing false or misleading statements to investors.

About Gibbs Law Group

Gibbs Law Group represents investors throughout the country in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Class Action Practice Group of the Year,” “Consumer Protection MVP,” and “Top Women Lawyers in California.”

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

EILEEN EPSTEIN
510.350.9728
EJE@CLASSLAWGROUP.COM

Gibbs Law Group

NASDAQ:NEO

Release Summary
Gibbs Law Group is investigating potential legal claims on behalf of NEO investors.
Release Versions
$Cashtags
Hashtags

Contacts

EILEEN EPSTEIN
510.350.9728
EJE@CLASSLAWGROUP.COM

More News From Gibbs Law Group

Class Action Lawsuit Filed Against Richtech Robotics; Investors Urged to Contact Award-Winning Firm, Gibbs Mura

OAKLAND, Calif.--(BUSINESS WIRE)--Gibbs Mura announces a class action lawsuit has been filed on behalf of Richtech Robotics Inc. (RR) investors....

Richtech Robotics Inc. Under Investigation After 20% Stock Drop

OAKLAND, Calif.--(BUSINESS WIRE)--Shares of Richtech Robotics Inc. (“Richtech Robotics”) fell over 20% in intraday trading on January 29, 2026, after Hunterbrook Media published a report accusing the company of misrepresenting its “collaboration” with Microsoft and missing its 10-K extended filing deadline. Gibbs Mura is investigating a potential Richtech Robotics Inc. (NASDAQ: RR) Securities Class Action Lawsuit concerning whether Richtech Robotics has violated federal securities laws by provi...

Kaiser Agrees To Historic $556 Million To Settle Whistleblower Lawsuit Over Alleged Medicare Fraud

OAKLAND, Calif.--(BUSINESS WIRE)--Gibbs Mura is pleased to announce that Kaiser Permanente has agreed to pay $556 million to resolve allegations of Medicare Advantage risk-adjustment fraud. This is believed to be the largest Medicare Part C qui tam settlement ever reached, and is one of the largest whistleblower settlements brought under the False Claims Act settlements in recent years. Our firm’s client, Ronda Osinek was the first whistleblower to file a complaint against Kaiser in the long-ru...
Back to Newsroom